Eli Lilly invests $1bn in Limerick manufacturing facilities

pharmafile | March 28, 2023 | News story | Manufacturing and Production  

Pharma company Eli Lilly is increasing its investment in its new manufacturing facilities in Limerick, Republic of Ireland. Today’s announcement of an additional $500m follows the initial $500m investment in January 2022


IDA Ireland interim CEO Mary Buckley said the new investment is a “testament to Ireland’s continued attractiveness as a location for investment.”


According to the company, the site will be its most technically advanced manufacturing site for existing monoclonal antibodies. More than 300 highly skilled jobs will be created along with the 500,000 square foot building. Lilly’s current facility in Cork employs more than 2,700 people.


Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations, commented: “Lilly is entering an exciting period of growth, and we are committed to delivering innovative medicines to patients around the world. Expanding our manufacturing footprint in North Carolina and Ireland enables us to continue to produce today’s medicines while providing additional capacity to manufacture the medicines of tomorrow.”


Minister for Enterprise, Trade and Employment Simon Coveney, TD, said Eli Lilly’s investment “highlights the wealth of talent we have to offer. The company produces key healthcare products which are aiding in the fight against a variety of the world’s most serious illnesses. All regional investments are hugely welcome, and the Government is fully supportive of such initiatives. I would like to congratulate the team and wish them every success for the future with this fantastic project.”


James Spargo

Related Content

No items found

Latest content